Myelodysplastic syndrome
Showing 1 - 25 of >10,000
Luspatercept in Korean Myelodysplastic Syndrome or ß-thalassemia
Not yet recruiting
- Myelodysplastic Syndrome
- Beta Thalassemia
-
Seoul, Korea, Republic ofBristol-Myers Squibb YH
Oct 3, 2023
Samples of Bone Marrow Aspiration From Myelodysplastic Syndrome
Recruiting
- Myelodysplastic Syndromes
- Blood test
-
Jerusalem, IsraelShaare Zedek Medical Center
Nov 27, 2023
Acute Myeloid Leukemia, MDS Trial (idarubicin, Cytarabine)
Not yet recruiting
- Acute Myeloid Leukemia
- Myelodysplastic Syndromes
- (no location specified)
Sep 18, 2023
MDS, Myelodysplastic Anemia, Myelodysplastic Syndrome With Isolated Del(5Q) Trial (description of MDS pzatient cohort)
Recruiting
- Myelodysplastic Syndromes
- +5 more
- description of MDS pzatient cohort
-
Brest, FranceChu Brest
Oct 27, 2022
Haplo-HSCT for Elderly Acute Leukemia/ Myelodysplastic Syndrome
Not yet recruiting
- Acute Leukemia
- Myelodysplastic Syndromes
-
Beijing, Beijing, ChinaPeking University People's Hospital
Jun 5, 2023
Acute Myeloid Leukemia, High-Risk and Very High-Risk MDS Trial (SGR-2921)
Not yet recruiting
- Acute Myeloid Leukemia
- High-Risk and Very High-Risk Myelodysplastic Syndromes
- (no location specified)
Jul 25, 2023
Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome Trial in Scottsdale, Cleveland,
Completed
- Chronic Myelomonocytic Leukemia
- +3 more
- Azacitidine
- +2 more
-
Scottsdale, Arizona
- +3 more
Jan 12, 2023
Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2 Trial in Boston (BXCL701)
Not yet recruiting
- Acute Myeloid Leukemia
- Myelodysplastic Syndrome With Excess Blasts-2
-
Boston, MassachusettsDana Farber Cancer Institute
Jan 26, 2023
Secondary Myelodysplastic Syndrome, Therapy-Related Myelodysplastic Syndrome Trial in Columbus (Azacitidine, Quality-of-Life
Recruiting
- Secondary Myelodysplastic Syndrome
- Therapy-Related Myelodysplastic Syndrome
- Azacitidine
- +3 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Dec 1, 2022
MDS, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic Trial in Newcastle (Subcutaneous azacitidine, Oral
Not yet recruiting
- Myelodysplastic Syndromes
- +3 more
- Subcutaneous azacitidine
- Oral decitabine/cedazuridine
-
Newcastle, New South Wales, AustraliaCalvary Mater Newcastle
May 29, 2023
Myelodysplastic Syndrome Trial in Japan (SyB C-1101 and Azacytidine)
Withdrawn
- Myelodysplastic Syndrome
- SyB C-1101 and Azacytidine
-
Nagoya, Aichi, Japan
- +3 more
Nov 14, 2022
Acute Myeloid Leukemia and Myelodysplastic Syndrome Trial in Tianjin (QLF32101)
Not yet recruiting
- Acute Myeloid Leukemia and Myelodysplastic Syndrome
-
Tianjin, Tianjin, ChinaInstitute of Hematology&Blood Diseases Hospital,Chinese Academy
Jan 27, 2023
MDS Trial in Seoul (cyclophosphamide, fludarabine, and antithymocyte globulin)
Active, not recruiting
- Myelodysplastic Syndromes
- cyclophosphamide, fludarabine, and antithymocyte globulin
-
Seoul, Korea, Republic ofAsan Medical Center, University of Ulsan College of Medicine
Oct 19, 2023
Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial (UAE Inhibitor TAK-243)
Not yet recruiting
- Myelodysplastic Syndrome
- +4 more
- UAE Inhibitor TAK-243
- (no location specified)
Oct 20, 2022
Myelodysplastic Syndrome Trial in Japan (SyB C-1101)
Completed
- Myelodysplastic Syndrome
- SyB C-1101
-
Nagoya, Aichi, Japan
- +8 more
Nov 14, 2022
MDS Trial (Yisui granule, Placebo)
Not yet recruiting
- MDS
- Yisui granule
- Placebo
- (no location specified)
Jan 13, 2023
Acute Myeloid Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia Trial in Houston (Decitabine, Quizartinib,
Recruiting
- Acute Myeloid Leukemia
- +4 more
- Decitabine
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Jan 27, 2023
Chronic Myelomonocytic Leukemia-0, Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2 Trial in Houston
Active, not recruiting
- Chronic Myelomonocytic Leukemia-0
- +5 more
-
Houston, TexasM D Anderson Cancer Center
Jan 18, 2023
Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Recurrent Chronic Myelomonocytic Leukemia Trial in Houston
Recruiting
- Chronic Myelomonocytic Leukemia
- +5 more
- Canakinumab
-
Houston, TexasM D Anderson Cancer Center
Dec 7, 2022
High Risk Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Houston
Completed
- High Risk Myelodysplastic Syndrome
- +2 more
- Daratumumab
-
Houston, TexasM D Anderson Cancer Center
Nov 21, 2022
Clonal Cytopenia of Undetermined Significance, Essential Thrombocythemia, Myelodysplastic Syndrome Trial in Los Angeles
Not yet recruiting
- Clonal Cytopenia of Undetermined Significance
- +4 more
- Biospecimen Collection
- +6 more
-
Los Angeles, California
- +1 more
Oct 4, 2023
Hematopoietic and Lymphoid Cell Tumor, Recurrent Acute Biphenotypic Leukemia, Recurrent Acute Myeloid Leukemia Trial in Houston
Recruiting
- Hematopoietic and Lymphoid Cell Neoplasm
- +6 more
- Omacetaxine Mepesuccinate
- Venetoclax
-
Houston, TexasM D Anderson Cancer Center
Dec 31, 2022
Higher Risk Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia Trial (AMG 176, Azacitidine)
Not yet recruiting
- Higher Risk Myelodysplastic Syndrome
- Chronic Myelomonocytic Leukemia
- AMG 176
- Azacitidine
- (no location specified)
Jul 29, 2022